Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Combination of CXD and Restrictive Ketogenic Diet Against MASLD

Clinical Trial Study on the Combination of CXD and Restrictive Ketogenic Diet in Treating MASLD

This study employed a single-center, randomized, investigator-blind, three-group parallel, stepwise controlled clinical trial. A total of 135 subjects were randomly assigned to receive either a low-carbohydrate diet intervention, a restrictive ketogenic diet intervention, or a decoction preparation of the Tucha Lipid-Reducing Formula combined with a restrictive ketogenic diet. The trial duration consisted of 8 weeks of treatment followed by 8 weeks of follow-up. During the trial, participants adhered to dietary calorie control and moderate exercise as instructed in health education, self-reported their height, weight, waist-to-hip ratio, and other general parameters, and had weekly blood ketone level monitoring. Liver ultrasound, fasting blood glucose, lipid profiles, blood ketones, liver function tests, serum creatinine, urea nitrogen levels, and scores on the Traditional Chinese Medicine Syndrome Scale were measured before treatment initiation and at the end of the 8-week treatment period.

Studieöversikt

Studietyp

Interventionell

Inskrivning (Beräknad)

135

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Age 18-50 years, regardless of gender
  • Meet the diagnostic criteria for MASLD
  • Meet the diagnostic criteria for dampness-heat accumulation syndrome in Traditional Chinese Medicine
  • Liver controlled attenuation parameter (CAP) ≥238 dB/m
  • Body mass index (BMI) ≥23 kg/m²
  • Possess adequate cognitive and comprehension abilities to understand the study content, its potential risks, and benefits;
  • Voluntarily participate in this study and personally sign the informed consent form

Exclusion Criteria:

  • Concurrent presence of other liver diseases that may lead to hepatic steatosis, specifically including drug-induced liver injury, alcoholic liver disease, autoimmune liver disease, viral hepatitis, and Wilson's disease
  • Concurrent severe dysfunction of major organs such as the heart, kidneys, or lungs, e.g., severe cardiac insufficiency (NYHA class III or higher), renal failure (estimated glomerular filtration rate <30 mL/min/1.73 m²), or acute exacerbation of chronic obstructive pulmonary disease
  • Subjects currently receiving treatment for MASLD
  • Concurrent presence of other severe systemic diseases, such as malignant tumors or active systemic lupus erythematosus
  • Known hypersensitivity or intolerance to any component of the study drug
  • Pregnant women, lactating women, or women of childbearing age who refuse effective contraceptive measures during the trial
  • Participation in other clinical trials within the past 3 months
  • Other circumstances deemed by the investigator unsuitable for participation in this study, such as severe mental disorders affecting compliance with the study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Placebo-jämförare: Low-carbon control group
The control group received a standardized low-carbohydrate diet (carbohydrates accounted for 25%-30% of total caloric intake).
Experimentell: KD group
Daily carbohydrate intake should not exceed 5%, with three consecutive ketogenic days per week implemented (selected according to the subject's preference).
Experimentell: CXD and KD group
In addition to a restrictive ketogenic diet intervention, the patients were administered a traditional Chinese medicine compound formula named Chazhu Xiaoli Formula for lipid reduction. Below is the composition of Chazhu Xiaozhi decoction: Camellia Sinensis Radix 15g, Atractylodis Rhizoma 15g, Herba Gynostemmatis Pentaphylli 15g, Ilicis Cornutae Folium 15g, Alismatis Rhizoma 9g, Nelumbinis Folium 6g, Crataegi Fructus 6g, Polygoni Orientalis Fructus 3g.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Controlled Attenuation Parameter (CAP) value
Tidsram: From enrollment to the end of treatment at 8 weeks
Use an elastography ultrasound device to measure liver fat content
From enrollment to the end of treatment at 8 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
BMI
Tidsram: From baseline to the end of the 8-week follow-up period
From baseline to the end of the 8-week follow-up period
Triglyceride(TG)
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure TG
From enrollment to the end of treatment at 8 weeks
Total blood cholesterol(TC)
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure TC
From enrollment to the end of treatment at 8 weeks
High-Density Lipoprotein(HDL)
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure HDL
From enrollment to the end of treatment at 8 weeks
Alanine Aminotransferase (ALT)
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure liver function
From enrollment to the end of treatment at 8 weeks
Aspartate Aminotransferase(AST)
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure liver function
From enrollment to the end of treatment at 8 weeks
Gamma-Glutamyl Transferase(GGT)
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure liver function
From enrollment to the end of treatment at 8 weeks
Blood glucose metabolism indicators
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure blood glucose
From enrollment to the end of treatment at 8 weeks
Traditional Chinese Medicine Syndrome Scoring System
Tidsram: From enrollment to the end of treatment at 8 weeks
The title is Traditional Chinese Medicine Syndrome Scale. The minimum score is 0 and the maximum is 6. Lower scores indicate better results.
From enrollment to the end of treatment at 8 weeks
Blood ketones
Tidsram: From baseline to the end of the 8-week follow-up period
Use a fully automated biochemical analyzer to measure blood ketones to indicate clinical safety
From baseline to the end of the 8-week follow-up period
Creatinine
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure creatinine to indicate clinical safety
From enrollment to the end of treatment at 8 weeks
Blood Urea Nitrogen
Tidsram: From enrollment to the end of treatment at 8 weeks
Use a fully automated biochemical analyzer to measure blood urea nitrogen to indicate clinical safety
From enrollment to the end of treatment at 8 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juli 2026

Primärt slutförande (Beräknad)

28 december 2026

Avslutad studie (Beräknad)

1 februari 2027

Studieregistreringsdatum

Först inskickad

27 maj 2026

Först inskickad som uppfyllde QC-kriterierna

6 juni 2026

Första postat (Faktisk)

10 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 juli 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

10 juli 2026

Senast verifierad

1 juni 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • KD20260527

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera